Augmentation of NVP-BEZ235's anticancer activity against human lung cancer cells by blockage of autophagy

Cancer Biology and Therapy

Volumn 12, Issue 6, 2011, Pages 549-555

  Xu, Cheng Xiong ^a   Zhao, Liqun ^a   Yue, Ping ^a   Fang, Guofu ^a   Tao, Hui ^a   Owonikoko, Taofeek K ^a   Ramalingam, Suresh S ^a   Khuri, Fadlo R ^a   Sun, Shi Yong ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Autophagy; BEZ235; Lung cancer; mTOR; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; CHLOROQUINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; LYSOSOME; MOUSE; NONHUMAN; REGULATORY MECHANISM; XENOGRAFT;

ANIMALS; APOPTOSIS; AUTOPHAGY; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CHLOROQUINE; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MICE; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-AKT; QUINOLINES; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052823576     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.12.6.16397     Document Type: Article

References (28)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin 2010; 60:277-300; PMID: 20610543; DOI: 10.3322/caac.20073.
2. West KA, Castillo SS, Dennis PA. Activation of the PI3K/Akt pathway and chemotherapeutic resistance. Drug Resist Updat 2002; 5:234-48; PMID: 12531180; DOI: 10.1016/S1368-7646(02)00120-6.
3. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat 2008; 11:32-50; PMID: 18166498; DOI: 10.1016/j.drup.2007.11.003.
4. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441:424-30; PMID: 16724053; DOI: 10.1038/ nature04869.
5. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 2005; 4:988-1004; PMID: 16341064; DOI: 10.1038/nrd1902.
6. Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91-9; PMID: 15261145; DOI: 10.1016/j.ccr.2004.06.007.
7. Makowski L, Hayes DN. Role of LKB1 in lung cancer development. Br J Cancer 2008; 99:683-8; PMID: 18728656; DOI: 10.1038/sj.bjc.6604515.
8. Ding L, Getz G, Wheeler DA, Mardis ER, McLellan MD, Cibulskis K, et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008; 455:1069-75; PMID: 18948947; DOI: 10.1038/ nature07423.
9. Chen YL, Law PY, Loh HH. Inhibition of PI3K/ Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents 2005; 5:575-89; PMID: 16305480; DOI: 10.2174/156801105774574649.
10. Sawyers CL. Will mTOR inhibitors make it as cancer drugs? Cancer Cell 2003; 4:343-8; PMID: 14667501; DOI: 10.1016/S1535-6108(03)00275-7.
11. Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol- 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008; 7:1851-63; PMID: 18606717; DOI: 10.1158/1535-7163.MCT-08-0017.
12. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008; 14:1351-6; PMID: 19029981; DOI: 10.1038/ nm.1890.
13. Konstantinidou G, Bey EA, Rabellino A, Schuster K, Maira MS, Gazdar AF, et al. Dual phosphoinositide- 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res 2009; 69:7644-52; PMID: 19789349; DOI: 10.1158/0008-5472.CAN-09-0823.
14. Faber AC, Li D, Song Y, Liang MC, Yeap BY, Bronson RT, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci USA 2009; 106:19503-8; PMID: 19850869; DOI: 10.1073/pnas.0905056106.
15. Mizushima N, Levine B, Cuervo AM, Klionsky DJ. Autophagy fights disease through cellular self-digestion. Nature 2008; 451:1069-75; PMID: 18305538; DOI: 10.1038/nature06639.
16. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008; 132:27-42; PMID: 18191218; DOI: 10.1016/j.cell.2007.12.018.
17. Rubinsztein DC, Gestwicki JE, Murphy LO, Klionsky DJ. Potential therapeutic applications of autophagy. Nat Rev Drug Discov 2007; 6:304-12; PMID: 17396135; DOI: 10.1038/nrd2272.
18. Levine B, Yuan J. Autophagy in cell death: an innocent convict? J Clin Invest 2005; 115:2679-88; PMID: 16200202; DOI: 10.1172/JCI26390.
19. Brachmann SM, Hofmann I, Schnell C, Fritsch C, Wee S, Lane H, et al. Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells. Proc Natl Acad Sci USA 2009; 106:22299-304; PMID: 20007781; DOI: 10.1073/pnas.0905152106.
20. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/ mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res 2008; 68:8022-30; PMID: 18829560; DOI: 10.1158/0008-5472.CAN-08-1385.
21. Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, Bodner S, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 1992; 7:171-80; PMID: 1311061.
22. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, et al. Synergistic augmentation of rapamycin-induced autophagy in malignant glioma cells by phosphatidylinositol-3-kinase/protein kinase B inhibitors. Cancer Res 2005; 65:3336-46; PMID: 15833867.
23. Fan QW, Cheng C, Hackett C, Feldman M, Houseman BT, Nicolaides T, et al. Akt and autophagy cooperate to promote survival of drug-resistant glioma. Sci Signal 2010; 3:81; PMID: 21062993; DOI: 10.1126/scisignal. 2001017.
24. Sun SY, Yue P, Dawson MI, Shroot B, Michel S, Lamph WW, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997; 57:4931-9; PMID: 9354460.
25. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295:868-72; PMID: 11786607; DOI: 10.1126/ science.1067081.
26. Wang X, Hawk N, Yue P, Kauh J, Ramalingam SS, Fu H, et al. Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy. Cancer Biol Ther 2008; 7:1952-8; PMID: 18981735; DOI: 10.4161/cbt.7.12.6944.
27. Liu X, Yue P, Zhou Z, Khuri FR, Sun SY. Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells. J Natl Cancer Inst 2004; 96:1769-80; PMID: 15572759; DOI: 10.1093/jnci/ djh322.
28. Sun SY, Yue P, Wu GS, El-Deiry WS, Shroot B, Hong WK, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999; 18:2357-65; PMID: 10327056; DOI: 10.1038/sj.onc.1202543.